2025 NERVE recipients
Meet 2025 NERVE Cohort
We are proud to announce $500,000 funding in support of neurotechnology innovation through the Neurotech Entrepreneurship to Validate Emerging Innovations (NERVE) program. Five trailblazing Canadian entrepreneurs have each secured $100,000 in non-dilutive funding and will accelerate the development of their neurotech ventures by participating in a 12-month program that offers mentorship, training, and business support.
As Canada's single largest award to catalyze early-stage neurotechnology, NERVE helps entrepreneurs to propel their innovations from concept to commercialization. This year's cohort is addressing critical challenges in concussion detection, surgical safety, neurosurgery, neurodegenerative disease treatment, and pain management.
Meet Andrew Cordssen-David, co-founder of HeadFirst from Waterloo, ON. HeadFirst is revolutionizing concussion detection with the first rapid, saliva-based screening tool that delivers objective results enabling informed decision-making in frontline care.
Introducing Mann Parikh, founder and CEO of NerView Surgical, based in Hamilton, ON. NerView Surgical is developing a novel non-invasive device for real-time serve visualization during surgery to prevent inadvertent nerve injuries.
Presenting Marc Shenouda, CEO of Neuropeutics Inc., based in Toronto, ON. Neuropeutics is a pharmaceutical company developing first-in-class targeted therapies to extend neurodegenerative disease patients' survival and improve their quality of life.
Meet Michael Tessier, COO and co-founder of Cohesys, based in Toronto, ON. Cohesys' BoneTape offers a novel approach to bone fracture repair, providing an investigational alternative to traditional plates, screws and meshes.
Introducing Stevie Foglia, founder and CEO of Neuro-Mod Inc., based in Toronto, ON. Neuro-Mod is focused on developing non-invasive therapeutics for pain management, leveraging augmented reality to deliver adaptive sensorimotor training for individuals with neck pain.